MedTrace Logo

Qishenyiqi Dripping Pill for Coronary Microvascular Disease

NCT06699420 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 162

Last updated 2024-11-21

No results posted yet for this study

Summary

To investigate the efficacy and safety of Qishenyiqi in patients with microvascular angina pectoris. Long-term follow-up of 1 year will be performed to evaluate the effect of Qishenyiqi on coronary flow reserve and adverse cardiovascular events in patients with coronary microvascular disease.

Conditions

  • Coronary Microvascular Disease

Interventions

DRUG

Qishenyiqi dripping pills 1 bag, three times a day

Qishenyiqi dripping pills, 1 bag once, three times a day, 12 months

DRUG

Placebo 1 bag, three times a day

Placebo, 1 bag once, three times a day, 12 months

Sponsors & Collaborators

  • Qilu Hospital of Shandong University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-08
Primary Completion
2025-12-31
Completion
2026-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06699420 on ClinicalTrials.gov